Healthtech DYAD raises £7.5m led by Sangha Capital with Carbide Ventures
This article covers DYAD, a healthtech startup, raising £7.5m in a series A funding round led by Sangha Capital, which closed in April 2026. The funding will accelerate rollout of its BetterLetter product across UK general practice and fund pilots of its GENIE system in secondary care and mental health services in the UK, Middle East and United States.
DYAD, a healthtech startup, has raised £7.5m in a series A funding round led by Sangha Capital, with participation from Bill Tai and Carbide Ventures. The round closed in April 2026 and brings the company’s total funding to £15m; DYAD says the money will accelerate rollout of its BetterLetter product across UK general practice and fund pilots of its GENIE system in secondary care and mental health services in the UK, Middle East and United States.
Why it matters
Primary care teams spend significant time extracting usable data from free-text clinical correspondence, creating administrative cost and potential delays in patient care. DYAD’s funding rounds up a modest but growing wave of investment into tools that convert unstructured clinical documents into structured records and actionable tasks. If the technology scales as promised, it could reduce manual coding work and improve the handover of clinical information between healthcare organisations.
Inside the product
DYAD’s core product is GENIE, a proprietary system that converts long, unstructured clinical documents into structured data. Rather than relying primarily on large language models, GENIE uses a multi-stage method the company calls Graph Enabled Information Extraction. Natural language processing first identifies medical entities and maps them to clinical coding taxonomies; knowledge graphs apply clinical rules and logic; LLMs are used only at the final stage to resolve remaining semantic ambiguity.
In primary care, GENIE powers BetterLetter, a clinical coding platform deployed in more than 200 GP surgeries. BetterLetter has processed over five million clinical documents to date and the company reports GENIE handles about 500,000 clinical letters each month. DYAD keeps a clinical coding team to review outputs and feed real-world corrections back into the product, and every suggestion is reviewed by a member of the practice team before it is written into the patient record.
The company positions the technology as aiming to reduce the estimated £300m annual burden associated with unstructured data transfer between secondary care and primary care by improving the speed and quality of coding and creating tasks that agentic systems can action.
Who are the investors?
DYAD’s £7.5m series A was led by Sangha Capital, with participation from angel investor Bill Tai and Carbide Ventures. The round closed in April 2026 and increases the company’s total raised to £15m.
In the announcement, Carolina Casas Forga, Investor at Sangha Capital, said:
DYAD is tackling a fundamental problem facing healthcare systems, vast amounts of valuable clinical information remain locked inside unstructured documents. The company has demonstrated both the strength of its technology and clear demand within primary care. We see a significant opportunity to build on that foundation and apply DYAD's technology across the wider healthcare system.
The capital is earmarked for faster UK primary care rollout of BetterLetter and for targeted pilots of GENIE in secondary care and mental health settings internationally. Sangha’s investment signals continued investor interest in pragmatic automation tools that integrate with clinical workflows rather than replace them.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
DYAD was founded six years ago by Dr Alexander Tayler and Dr Steven Hamblin. The founders have focussed on building a system that combines automated extraction with clinical oversight and human-in-the-loop learning.
In the announcement, Alexander Tayler, Co-founder & CEO, said:
Some of the most important patient information is still trapped in documents that existing systems cannot properly integrate, creating an unnecessary administrative burden for healthcare teams. More than 200 GP surgeries are now using our technology, benefitting from a purpose built world model for clinical coding and agentic platform for healthcare administration. This investment will allow us to accelerate that growth and take our technology into other parts of healthcare.
The bigger picture
DYAD’s raise sits within a broader trend of targeted healthtech investment focused on interoperability, workflow automation and improving clinical data quality. The company’s emphasis on combining rule-based knowledge graphs with selective use of LLMs reflects growing investor and provider caution about over-reliance on black-box models for clinical decisions. For the NHS and health systems abroad, practical gains often come from incremental improvements to administrative flows and record completeness rather than wholesale platform replacement.
As startups and investors continue to explore ways to make clinical data more usable, expect more pilots that test integration into existing NHS workflows and targeted deployments in areas such as mental health and secondary care where unstructured notes are abundant.
They've invested in DYAD
Get to know these healthtech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 Sangha Capital( ) Geneva, Switzerland  | ||||
 Carbide Ventures( ) Carbide Ventures is an early-stage venture capital firm focused on high-convicti... Palo Alto, US  | GeneralistHealthtech | |||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK